Evidence map›Paper›PMID 28525756›Full record

ArticleCell2017

Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.

Xuelian Zhao, Katie A Howell, Shihua He, Jennifer M Brannan, Anna Z Wec, Edgar Davidson, Hannah L Turner, Chi-I Chiang, Lin Lei, J Maximilian Fels and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Monoclonal Antibody Production Against Filoviruses from Immunized Mice.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Xuelian ZhaoInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20878, USA.
Katie A HowellIntegrated BioTherapeutics, Rockville, MD 20850, USA.
Shihua HeSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; Deparment of Medical Microbiology, University of Manitoba, MB R3E 0J9, Canada.
Jennifer M BrannanUS Army Medical Research Institute of Infectious Diseases, Frederick, MD 21701, USA.
Anna Z WecDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Edgar DavidsonIntegral Molecular, Philadelphia, PA 19104, USA.
Hannah L TurnerDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Chi-I ChiangInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20878, USA.
Lin LeiInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20878, USA.
J Maximilian FelsDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Hong VuIntegrated BioTherapeutics, Rockville, MD 20850, USA.
Sergey ShuleninIntegrated BioTherapeutics, Rockville, MD 20850, USA.
Ashley N TuronisIntegrated BioTherapeutics, Rockville, MD 20850, USA.
Ana I KuehneUS Army Medical Research Institute of Infectious Diseases, Frederick, MD 21701, USA.
Guodong LiuSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; Deparment of Medical Microbiology, University of Manitoba, MB R3E 0J9, Canada.
Mi TaIntegral Molecular, Philadelphia, PA 19104, USA.
Yimeng WangInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20878, USA.
Christopher SundlingImmunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia.
Yongli XiaoLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Jennifer S SpenceDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Benjamin J DoranzIntegral Molecular, Philadelphia, PA 19104, USA.
Frederick W HoltsbergIntegrated BioTherapeutics, Rockville, MD 20850, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
John M DyeUS Army Medical Research Institute of Infectious Diseases, Frederick, MD 21701, USA.
Xiangguo QiuSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; Deparment of Medical Microbiology, University of Manitoba, MB R3E 0J9, Canada.
Yuxing LiInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20878, USA; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: liy@ibbr.umd.edu.
M Javad AmanIntegrated BioTherapeutics, Rockville, MD 20850, USA. Electronic address: javad@integratedbiotherapeutics.com.

Funding

Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAI, JONATHAN R. · 2014 to 2018
$29.6M
Evolution of anti-filovirus B cell responses and mechanisms of protectionR01AI126587 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, LI, YUXING · 2017 to 2021
$3.7M
Structure-guided redesign of monoclonal antibodies targeting conserved filovirus epitopesR43AI124765 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD · 2016 to 2016
$284k
NIAID NIH HHS HHSN272201400058CNIAID NIH HHS R01 AI126587NIAID NIH HHS R43 AI124765NIAID NIH HHS U19 AI109762
6 · The paper itself

Abstract

While neutralizing antibodies are highly effective against ebolavirus infections, current experimental ebolavirus vaccines primarily elicit species-specific antibody responses. Here, we describe an immunization-elicited macaque antibody (CA45) that clamps the internal fusion loop with the N terminus of the ebolavirus glycoproteins (GPs) and potently neutralizes Ebola, Sudan, Bundibugyo, and Reston viruses. CA45, alone or in combination with an antibody that blocks receptor binding, provided full protection against all pathogenic ebolaviruses in mice, guinea pigs, and ferrets. Analysis of memory B cells from the immunized macaque suggests that elicitation of broadly neutralizing antibodies (bNAbs) for ebolaviruses is possible but difficult, potentially due to the rarity of bNAb clones and their precursors. Unexpectedly, germline-reverted CA45, while exhibiting negligible binding to full-length GP, bound a proteolytically remodeled GP with picomolar affinity, suggesting that engineered ebolavirus vaccines could trigger rare bNAb precursors more robustly. These findings have important implications for developing pan-ebolavirus vaccine and immunotherapeutic cocktails.

Indexed as

Amino Acid SequenceAnimalsAntibodies, NeutralizingAntibodies, ViralComplementarity Determining RegionsCross ReactionsEbola VaccinesEbolavirusEpitope MappingEpitopes, B-LymphocyteFemaleFerretsGuinea PigsHemorrhagic Fever, EbolaImmunoglobulin Fab FragmentsMacaca fascicularisAntibodies, NeutralizingAntibodies, ViralComplementarity Determining RegionsEbola VaccinesEpitopes, B-LymphocyteImmunoglobulin Fab Fragments

Identifiers

PMID28525756
PMCPMC5803079

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.